Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia

NCT01230775 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythaemia

Interventions

DRUG: Anagrelide retard
DRUG: Placebo

Sponsor

AOP Orphan Pharmaceuticals AG